author-photo

Peter King

Medical University of South Carolina

11

Papers

430

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

2011 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (28)
165 JNJ-26483327, a second-generation spectrum-targeted protein tyrosine kinase inhibitor with superior characteristics in advanced cancer models

2010 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)
JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

2009 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (150)
568 POSTER Selective inhibition of Met kinase activity impairs metastatic cancer cell motility and survival

2008 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

2007 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (83)
587 POSTER Efficacy of the novel multi-targeted kinase inhibitor JNJ-26483327 in experimental brain and bone metastases models

2006 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)
588 POSTER JNJ-26483327 is a novel multi-targeted tyrosine kinase inhibitor with cellular activity against EGFR, Her2, Src and VEGFR3

2006 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (1)
Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR.

2005 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (23)